Usmani Zafar A, Carson Kristin V, Heslop Karen, Esterman Adrian J, De Soyza Anthony, Smith Brian J
Department of Respiratory Medicine, The Queen Elizabeth Hospital, 4A, Main Building, 28 Woodville Road, Woodville South, Adelaide, Australia, SA 5011.
School of Medicine, The University of Adelaide, Adelaide, Australia.
Cochrane Database Syst Rev. 2017 Mar 21;3(3):CD010673. doi: 10.1002/14651858.CD010673.pub2.
Chronic obstructive pulmonary disease (COPD) (commonly referred to as chronic bronchitis and emphysema) is a chronic lung condition characterised by the inflammation of airways and irreversible destruction of pulmonary tissue leading to progressively worsening dyspnoea. It is a leading international cause of disability and death in adults. Evidence suggests that there is an increased prevalence of anxiety disorders in people with COPD. The severity of anxiety has been shown to correlate with the severity of COPD, however anxiety can occur with all stages of COPD severity. Coexisting anxiety and COPD contribute to poor health outcomes in terms of exercise tolerance, quality of life and COPD exacerbations. The evidence for treatment of anxiety disorders in this population is limited, with a paucity of evidence to support the efficacy of medication-only treatments. It is therefore important to evaluate psychological therapies for the alleviation of these symptoms in people with COPD.
To assess the effects of psychological therapies for the treatment of anxiety disorders in people with chronic obstructive pulmonary disease.
We searched the specialised registers of two Cochrane Review Groups: Cochrane Common Mental Disorders (CCMD) and Cochrane Airways (CAG) (to 14 August 2015). The specialised registers include reports of relevant randomised controlled trials from The Cochrane Library, MEDLINE, Embase, and PsycINFO. We carried out complementary searches on PsycINFO and CENTRAL to ensure no studies had been missed. We applied no date or language restrictions.
We considered all randomised controlled trials (RCTs), cluster-randomised trials and cross-over trials of psychological therapies for people (aged over 40 years) with COPD and coexisting anxiety disorders (as confirmed by recognised diagnostic criteria or a validated measurement scale), where this was compared with either no intervention or education only. We included studies in which the psychological therapy was delivered in combination with another intervention (co-intervention) only if there was a comparison group that received the co-intervention alone.
Two review authors independently screened citations to identify studies for inclusion and extracted data into a pilot-tested standardised template. We resolved any conflicts that arose through discussion. We contacted authors of included studies to obtain missing or raw data. We performed meta-analyses using the fixed-effect model and, if we found substantial heterogeneity, we reanalysed the data using the random-effects model.
We identified three prospective RCTs for inclusion in this review (319 participants available to assess the primary outcome of anxiety). The studies included people from the outpatient setting, with the majority of participants being male. All three studies assessed psychological therapy (cognitive behavioural therapy) plus co-intervention versus co-intervention alone. We assessed the quality of evidence contributing to all outcomes as low due to small sample sizes and substantial heterogeneity in the analyses. Two of the three studies had prespecified protocols available for comparison between prespecified methodology and outcomes reported within the final publications.We observed some evidence of improvement in anxiety over 3 to 12 months, as measured by the Beck Anxiety Inventory (range from 0 to 63 points), with psychological therapies performing better than the co-intervention comparator arm (mean difference (MD) -4.41 points, 95% confidence interval (CI) -8.28 to -0.53; P = 0.03). There was however, substantial heterogeneity between the studies (I = 62%), which limited the ability to draw reliable conclusions. No adverse events were reported.
AUTHORS' CONCLUSIONS: We found only low-quality evidence for the efficacy of psychological therapies among people with COPD with anxiety. Based on the small number of included studies identified and the low quality of the evidence, it is difficult to draw any meaningful and reliable conclusions. No adverse events or harms of psychotherapy intervention were reported.A limitation of this review is that all three included studies recruited participants with both anxiety and depression, not just anxiety, which may confound the results. We downgraded the quality of evidence in the 'Summary of findings' table primarily due to the small sample size of included trials. Larger RCTs evaluating psychological interventions with a minimum 12-month follow-up period are needed to assess long-term efficacy.
慢性阻塞性肺疾病(COPD)(通常称为慢性支气管炎和肺气肿)是一种慢性肺部疾病,其特征为气道炎症和肺组织的不可逆破坏,导致呼吸困难逐渐加重。它是成年人残疾和死亡的主要国际原因。有证据表明,COPD患者中焦虑症的患病率有所增加。焦虑的严重程度已被证明与COPD的严重程度相关,然而,焦虑可发生在COPD严重程度的所有阶段。并存的焦虑和COPD在运动耐力、生活质量和COPD急性加重方面会导致不良健康结局。该人群焦虑症治疗的证据有限,缺乏支持仅药物治疗疗效的证据。因此,评估心理治疗对缓解COPD患者这些症状的作用非常重要。
评估心理治疗对慢性阻塞性肺疾病患者焦虑症的治疗效果。
我们检索了两个Cochrane综述小组的专业注册库:Cochrane常见精神障碍(CCMD)和Cochrane气道(CAG)(截至2015年8月14日)。专业注册库包括来自Cochrane图书馆、MEDLINE、Embase和PsycINFO的相关随机对照试验报告。我们在PsycINFO和CENTRAL上进行了补充检索,以确保没有遗漏任何研究。我们未设置日期或语言限制。
我们纳入了所有针对年龄超过40岁且并存焦虑症(经公认的诊断标准或经过验证的测量量表确认)的COPD患者的心理治疗随机对照试验(RCT)、整群随机试验和交叉试验,将其与无干预或仅教育进行比较。仅当存在单独接受联合干预的对照组时,我们才纳入心理治疗与另一种干预(联合干预)相结合的研究。
两位综述作者独立筛选文献以确定纳入研究,并将数据提取到经过预试验的标准化模板中。我们通过讨论解决出现的任何冲突。我们联系纳入研究的作者以获取缺失或原始数据。我们使用固定效应模型进行荟萃分析,如果发现存在实质性异质性,则使用随机效应模型重新分析数据。
我们确定了三项前瞻性RCT纳入本综述(319名参与者可用于评估焦虑的主要结局)。这些研究纳入了门诊患者,大多数参与者为男性。所有三项研究均评估了心理治疗(认知行为疗法)加联合干预与单独联合干预的效果。由于样本量小且分析中存在实质性异质性,我们将所有结局的证据质量评估为低。三项研究中的两项有预先指定的方案,可用于比较预先指定的方法与最终出版物中报告的结局。我们观察到一些证据表明,通过贝克焦虑量表(范围为0至63分)测量,在3至12个月内焦虑有所改善,心理治疗的效果优于联合干预对照组(平均差(MD)-4.41分,95%置信区间(CI)-8.28至-0.53;P = 0.03)。然而,研究之间存在实质性异质性(I² = 62%),这限制了得出可靠结论的能力。未报告不良事件。
我们发现,对于患有焦虑症的COPD患者,心理治疗疗效的证据质量仅为低质量。基于纳入研究数量少且证据质量低,难以得出任何有意义且可靠的结论。未报告心理治疗干预的不良事件或危害。本综述的一个局限性是,所有三项纳入研究招募的参与者既有焦虑症又有抑郁症,而不仅仅是焦虑症,这可能会混淆结果。我们在“结果总结”表中降低了证据质量,主要原因是纳入试验的样本量小。需要进行更大规模的RCT,评估心理干预并至少随访12个月,以评估长期疗效。